公开(公告)号：US20210205535A1

公开(公告)日：2021-07-08

申请号：US17142425

申请日：2021-01-06

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on the history of glucose values and insulin deliveries for the user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal or exercise by the user.

公开(公告)号：US20210128831A1

公开(公告)日：2021-05-06

申请号：US17085344

申请日：2020-10-30

Applicant: Insulet Corporation

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Rangarajan NARAYANASWAMI ,  David NAZZARO ,  Thomas METZMAKER

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/13 ,  G16H20/17 ,  G16H40/67 ,  G06N20/00 ,  G06N5/04

Abstract: A wearable drug delivery device and method for optimizing performance thereof are provided. A system may include a processor operable with memory, and a drug delivery device and sensor coupled to a user, the sensor operable to detect characteristics of the delivery device. A receiver operable on the processor receives an input signal from the sensor, the input signal representing the detected characteristics. A controller operable on the processor receives the input signal from the receiver, and retrieves, from memory, a baseline characteristics. The controller may determine a location of the delivery device and a tissue profile of the injection location based on a comparison between the detected characteristics and the baseline characteristics. The controller may further control or modify delivery of a liquid drug from the delivery device in response to the location of the delivery device.

公开(公告)号：US20250144295A1

公开(公告)日：2025-05-08

申请号：US19017941

申请日：2025-01-13

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US20250082842A1

公开(公告)日：2025-03-13

申请号：US18883710

申请日：2024-09-12

Applicant: INSULET CORPORATION

Inventor： John BUSSIERE ,  Joon Bok LEE ,  Yibin ZHENG ,  Ashutosh ZADE ,  Jason O’CONNOR

IPC: A61M5/142 ,  A61M5/172

Abstract: In an aspect, an adhesive patch is presented. The adhesive patch has a top surface configured to adhere to a wearable medical device. The adhesive patch has a bottom surface opposite the top surface, wherein the bottom surface includes an adhesive layer configured to adhere to a user's skin. The adhesive patch has a first perforation extending through the top and bottom surfaces, the first perforation configured to receive a piercing element from the wearable medical device.

公开(公告)号：US20240009393A1

公开(公告)日：2024-01-11

申请号：US18474566

申请日：2023-09-26

Applicant: INSULET CORPORATION

Inventor： Steven CARDINALI ,  Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  A61B5/145

CPC classification number: A61M5/1723 ,  G16H20/17 ,  G16H10/60 ,  A61B5/14532 ,  G16H15/00

Abstract: Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.

公开(公告)号：US20230381414A1

公开(公告)日：2023-11-30

申请号：US18323538

申请日：2023-05-25

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  G16H10/60 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  G16H10/60

Abstract: Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

公开(公告)号：US20230377706A1

公开(公告)日：2023-11-23

申请号：US18199641

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  William WHITELEY ,  Jason O’CONNOR

IPC: G16H20/10 ,  A61B5/145 ,  A61B5/00 ,  G16H40/63

CPC classification number: G16H20/10 ,  A61B5/14532 ,  A61B5/4839 ,  G16H40/63

Abstract: The exemplary embodiments may dynamically adjust an Insulin on Board (JOB) profile for a user of a medicament delivery system to customize the IOB profile to the user based on recent glucose level history and insulin deliveries rather than use the conventional static IOB profiles that are based on population averages. The exemplary embodiments may calculate a Duration of Insulin Action (DIA) for a user from the customized insulin decay curves. The exemplary embodiments may generate and send notifications to the user to help reduce the DIA of the user and/or to keep the DIA of the user from rising. The exemplary embodiments may aim to not overly constrain insulin delivery due to the contribution of insulin boluses to JOB.

公开(公告)号：US20220395638A1

公开(公告)日：2022-12-15

申请号：US17839647

申请日：2022-06-14

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR

IPC: A61M5/172

Abstract: The disclosed embodiments are directed to methods for adjusting, on a per individual basis, the maximum delivery limit of insulin delivered to a diabetic person via an automatic insulin delivery system, particularly for a diabetic who receives basal or bolus doses of insulin via an automatic insulin delivery system. Various embodiments of the method disclosed herein may be incorporated into a dosing algorithm of an automatic insulin delivery system.

公开(公告)号：US20220361812A1

公开(公告)日：2022-11-17

申请号：US17736380

申请日：2022-05-04

Applicant: Insulet Corporation

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Jay JANTZ ,  Joon Bok LEE

IPC: A61B5/00 ,  G16H20/17 ,  G16H10/60 ,  G16H50/20 ,  G16H50/50 ,  A61M5/172 ,  A61B5/145

Abstract: The disclosed embodiments are directed to systems and methods for providing optimized, individualized bolus dosing of insulin based on a macronutrient profile of meals ingested by the patient. Optimized bolus dosing may be provided by varying the overall quantity of insulin delivered in the post-prandial window, as well as the split between a portion of the insulin delivered immediately after the meal and a portion of the insulin delivered later in the post-prandial window, based on an analysis of the macronutrient profile of the meal and the behavior of the blood glucose trace of the patient from past meals.

公开(公告)号：US20220331519A1

公开(公告)日：2022-10-20

申请号：US17718663

申请日：2022-04-12

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61B5/145 ,  A61B5/1495 ,  A61M5/142 ,  G16H40/40

Abstract: Exemplary embodiments may compensate for loss of calibration by sensors that provide sensed analyte measurements to delivery devices. The exemplary embodiments may obtain one or more calibrated analyte measurements, such as by using techniques to obtain that the analyte measurement value that are known to produce properly calibrated analyte values. The one or more calibrated analyte measurements are compared to a recent analyte measurement to determine a negative or positive offset. The offset may be added to the recent analyte measurement to generate an updated analyte measurement that reflects the calibrated analyte measurement. In addition, past analyte measurement values within a time window may be updated as well by adding the offset to the past analyte measurement values. The exemplary embodiments may also compensate for the past over-delivery or under-delivery of an agent by the delivery device due to the loss of calibration.